Pulmatrix (NASDAQ:PULM) is a clinical‐stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life‐threatening respiratory diseases. Utilizing its proprietary iSPERSE® particle technology, Pulmatrix aims to improve drug delivery to the deep lung by producing fine, dispersible dry‐powder formulations. The company’s approach is designed to enhance local drug concentration in the lungs while minimizing systemic exposure, offering potential safety and efficacy advantages over traditional delivery methods.
The company’s lead programs include PUR1900, an inhaled formulation of treprostinil for the treatment of pulmonary arterial hypertension, and PUR0200, an inhaled formulation of opelconazole targeting serious fungal infections in patients with cystic fibrosis and bronchiectasis. Both candidates have advanced through early‐stage clinical trials, demonstrating favorable tolerability and pharmacokinetic profiles. Pulmatrix also maintains a preclinical pipeline addressing additional acute and chronic pulmonary indications, leveraging the versatility of its iSPERSE platform to explore novel therapeutic areas.
Founded in 2006 and headquartered in Cambridge, Massachusetts, Pulmatrix conducts its research and development activities primarily in the United States, with clinical trial sites spanning North America and Europe. The company collaborates with academic institutions, contract research organizations, and strategic industry partners to advance its inhaled product candidates through regulatory pathways. Pulmatrix’s work aims to address significant unmet medical needs in both common and orphan lung diseases, positioning the company to capture opportunities in global respiratory markets.
Pulmatrix is led by a management team with extensive experience in respiratory drug development, regulatory affairs, and commercial strategy. Chief Executive Officer Paul M. H. Lee, Ph.D., oversees the company’s strategic direction, supported by a leadership bench that includes experts in pharmaceutical engineering, clinical operations, and business development. Under their guidance, Pulmatrix continues to pursue key regulatory milestones, manufacturing scale‐up, and potential licensing or partnership arrangements to bring its inhaled therapies closer to patients in need.
